《国际文传(中国)电讯社》采访杨昌顺:药企在中国基本药物市场竞争


《国际文传(中国)电讯社》采访杨昌顺:

Pharma companies vying for China's

grassroots drug market

 杨昌顺博客首页:www.yangchangshun.com

杨昌顺原创及相关文章                 

 by Karl Zhong

Shanghai. April 6. INTERFAX-CHINA - Pharmaceutical companies are increasingly concentrating their efforts on China's emerging grassroots drug market given that the ongoing health care reform has placed a large emphasis on grassroots medical institutions.

In recent years, pharmaceutical companies such as Beijing Double Crane Pharmaceutical Co. Ltd., Shandong Lukang Pharmaceutical Co. Ltd., Tianjin Tasly Pharmaceutical Co. Ltd. and Shanghai Hutchison Pharmaceuticals Ltd. have started focusing on developing the grassroots medical market in China. Their marketing strategies mainly include launching training programs for doctors from township clinics and community health medical institutions as well as setting up grassroots sales networks.

Double Crane Pharma's sales network covers 600 counties in China, with at least one sales representative in each county responsible for the company's marketing efforts. The company sold more than 900 million tablets of its antihypertensive drug Jiang Ya Ling Hao in 2009, as compared with about 800 million tablets in 2008.

In 2009, Lukang Pharma achieved over 40 percent growth in penicillin product sales in the grassroots drug market, marked by a strong growth momentum.

Zhejiang Conba Pharmaceutical Co. Ltd. launched a Grassroots Doctors Club campaign in 2006, which aims to better educate doctors in grassroots medical institutions on drug use. Guangdong Huanan Pharmacy Ltd. recently started promoting its brand in rural areas using outdoor advertisements and distribution of product brochures at markets.

"China's grassroots drug market is growing fast and brand name generic drug manufacturers could very well become the winners in this market," Guo Fanli, a pharmaceutical analyst from Zhenzhen Zhongzhe Investment Co. Ltd., told Interfax on April 1.

Not surprisingly, foreign pharmaceutical companies are also vying for a slice of China's grassroots drug market. Starting June 2009, Bayer HealthCare has worked with the Ministry of Health on organizing training programs for doctors from community health medical institutions.

"We can already see that foreign companies have formulated new marketing strategies and detailed implementation plans targeted at the grassroots drug market. In fact, no pharmaceutical company in China can neglect the emerging grassroots drug market," Yang Changshun, Shanghai Haihong Group Chaohu C-dragon Pharmaceutical Co. Ltd.'s marketing director, told Interfax on April 2.

Bidding procurement exercises for essential drugs in various provinces have attracted both domestic and foreign companies.

During Jiangsu Province's drug bidding procurement exercise for grassroots medical institutions at the end of last year, Wyeth, Eli Lilly, and Johnson & Johnson successfully won bids after reducing their product prices. Wyeth set its dextromethorphan hydrobromide at RMB 15 ($2.19), despite its drugstore price of RMB 19 ($2.78) while its caltrate was set at RMB 49.27 ($7.21), as compared to RMB 60 ($8.78) in drugstores.

"Whether foreign drug companies will see rising sales volumes will depend on if they can tailor their doctor education marketing campaigns in large cities to fit grassroots medical institutions and if their products face sharp competition from domestic products," Yang said.

Furthermore, foreign drug companies which won bids should not rest on their laurels but instead must continue their marketing efforts including collaborating with agents and setting up dedicated marketing teams, Yang added.

According to Guo, there are also opportunities for foreign companies in the grassroots non-essential drug market since there are rural residents who can afford higher-priced drugs too.

In the meantime, drug companies will need to keep tabs on whether their drugs which did not make it onto the national essential drug list are eventually included in the provincial-level essential drug lists," Yang said.

 

 

杨昌顺   www.yangchangshun.com

聚焦医药,紧跟政策,关注热点,传播理念 

[email protected] 

 

杨昌顺原创及相关文章

更多杨昌顺的医药咨讯

 

 

 

国际文传电讯社简介

国际文传电讯社成立于1989 年。 作为一家专业并客观的新闻社,国际文传电讯社在全球范围享有盛名。

从九十年代初期起,国际文传电讯社一直是俄罗斯与原苏联国家新闻的主要提供者。同时也是该地区最经常被引用的信息源。在过去几年中,国际文传电讯社作为国际文传信息服务集团的一员 , 更成为中国以及中欧新兴市场政治与商业新闻的领先提供者。目前,在俄罗斯、独联体、中国与中欧国家有 30个公司在国际文传的品牌下运营。国际文传信息服务集团用俄语、英语、乌克兰语、哈萨克语和德语发布新闻并提供大约 100种特定的产品。

国际文传从 2000年3月起开始在中国进行报导。2002年夏天俄罗斯国有商业银行俄罗斯外贸银行加入我们的中国项目,进一步推进了我们在中国业务的发展。国际文传电讯社中国分社为该集团最新的一个分社,已在北京,上海和香港设立了记者站或联络处。

国际文传的记者每天通过与官员、行业领导者、分析家、研究员,学者及遍布全国的广泛联系网络直接沟通进行报道。 我们按照最高的标准进行新闻报道和编辑管理,这对于在一个新兴经济体中发掘信息是至关重要的。精确、团队合作、正直和质量是国际文传记者们的格言。